Grade ≥3 treatment-emergent adverse events
| AE term . | All . | HMB . | LMB . |
|---|---|---|---|
| Any grade ≥3 | 23 (100) | 12 (100) | 11 (100) |
| Neutrophil count decreased | 23 (100) | 12 (100) | 11 (100) |
| Anemia | 17 (73.9) | 10 (83.3) | 7 (63.6) |
| Platelet count decreased | 16 (69.6) | 10 (83.3) | 6 (54.5) |
| Fever | 6 (26.1) | 4 (33.3) | 2 (18.2) |
| Hypotension | 5 (21.7) | 2 (16.7) | 3 (27.3) |
| Headache | 5 (21.7) | 2 (16.7) | 3 (27.3) |
| Fatigue | 3 (13) | 2 (16.7) | 1 (9.1) |
| Hypertension | 6 (26.1) | 4 (33.3) | 2 (18.2) |
| Encephalopathy | 4 (17.4) | 3 (25) | 1 (9.1) |
| Febrile neutropenia | 4 (17.4) | 3 (25) | 1 (9.1) |
| Hyperglycemia | 4 (17.4) | 3 (25) | 1 (9.1) |
| Hypophosphatemia | 4 (17.4) | 2 (16.7) | 2 (18.2) |
| Dyspnea | 2 (8.7) | 0 (0) | 2 (18.2) |
| Fibrinogen decreased | 3 (13) | 3 (25) | 0 (0) |
| Sepsis | 3 (13) | 3 (25) | 0 (0) |
| Hypoxia | 2 (8.7) | 2 (16.7) | 0 (0) |
| Back pain | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Hypocalcemia | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Lymphocyte count decreased | 2 (8.7) | 2 (16.7) | 0 (0) |
| Rash maculo-papular | 1 (4.3) | 1 (8.3) | 0 (0) |
| White blood cell decreased | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Abdominal pain | 1 (4.3) | 1 (8.3) | 0 (0) |
| Activated PTT prolonged | 1 (4.3) | 0 (0) | 1 (9.1) |
| Alanine aminotransferase increased | 1 (4.3) | 1 (8.3) | 0 (0) |
| Arthralgia | 1 (4.3) | 0 (0) | 1 (9.1) |
| Bacteremia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Catheter-related infection | 1 (4.3) | 0 (0) | 1 (9.1) |
| Chest pain-cardiac | 1 (4.3) | 1 (8.3) | 0 (0) |
| Colonic perforation | 1 (4.3) | 1 (8.3) | 0 (0) |
| Dehydration | 1 (4.3) | 1 (8.3) | 0 (0) |
| Diabetic ketoacidosis | 1 (4.3) | 1 (8.3) | 0 (0) |
| Gastric hemorrhage | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyperkalemia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyperphosphatemia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyponatremia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Left pleural effusion | 1 (4.3) | 1 (8.3) | 0 (0) |
| Lung infection | 1 (4.3) | 1 (8.3) | 0 (0) |
| Muscle weakness lower limb | 1 (4.3) | 1 (8.3) | 0 (0) |
| Respiratory failure | 1 (4.3) | 1 (8.3) | 0 (0) |
| Somnolence | 1 (4.3) | 1 (8.3) | 0 (0) |
| Thromboembolic event | 1 (4.3) | 1 (8.3) | 0 (0) |
| Wound infection | 1 (4.3) | 1 (8.3) | 0 (0) |
| AE term . | All . | HMB . | LMB . |
|---|---|---|---|
| Any grade ≥3 | 23 (100) | 12 (100) | 11 (100) |
| Neutrophil count decreased | 23 (100) | 12 (100) | 11 (100) |
| Anemia | 17 (73.9) | 10 (83.3) | 7 (63.6) |
| Platelet count decreased | 16 (69.6) | 10 (83.3) | 6 (54.5) |
| Fever | 6 (26.1) | 4 (33.3) | 2 (18.2) |
| Hypotension | 5 (21.7) | 2 (16.7) | 3 (27.3) |
| Headache | 5 (21.7) | 2 (16.7) | 3 (27.3) |
| Fatigue | 3 (13) | 2 (16.7) | 1 (9.1) |
| Hypertension | 6 (26.1) | 4 (33.3) | 2 (18.2) |
| Encephalopathy | 4 (17.4) | 3 (25) | 1 (9.1) |
| Febrile neutropenia | 4 (17.4) | 3 (25) | 1 (9.1) |
| Hyperglycemia | 4 (17.4) | 3 (25) | 1 (9.1) |
| Hypophosphatemia | 4 (17.4) | 2 (16.7) | 2 (18.2) |
| Dyspnea | 2 (8.7) | 0 (0) | 2 (18.2) |
| Fibrinogen decreased | 3 (13) | 3 (25) | 0 (0) |
| Sepsis | 3 (13) | 3 (25) | 0 (0) |
| Hypoxia | 2 (8.7) | 2 (16.7) | 0 (0) |
| Back pain | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Hypocalcemia | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Lymphocyte count decreased | 2 (8.7) | 2 (16.7) | 0 (0) |
| Rash maculo-papular | 1 (4.3) | 1 (8.3) | 0 (0) |
| White blood cell decreased | 2 (8.7) | 1 (8.3) | 1 (9.1) |
| Abdominal pain | 1 (4.3) | 1 (8.3) | 0 (0) |
| Activated PTT prolonged | 1 (4.3) | 0 (0) | 1 (9.1) |
| Alanine aminotransferase increased | 1 (4.3) | 1 (8.3) | 0 (0) |
| Arthralgia | 1 (4.3) | 0 (0) | 1 (9.1) |
| Bacteremia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Catheter-related infection | 1 (4.3) | 0 (0) | 1 (9.1) |
| Chest pain-cardiac | 1 (4.3) | 1 (8.3) | 0 (0) |
| Colonic perforation | 1 (4.3) | 1 (8.3) | 0 (0) |
| Dehydration | 1 (4.3) | 1 (8.3) | 0 (0) |
| Diabetic ketoacidosis | 1 (4.3) | 1 (8.3) | 0 (0) |
| Gastric hemorrhage | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyperkalemia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyperphosphatemia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Hyponatremia | 1 (4.3) | 1 (8.3) | 0 (0) |
| Left pleural effusion | 1 (4.3) | 1 (8.3) | 0 (0) |
| Lung infection | 1 (4.3) | 1 (8.3) | 0 (0) |
| Muscle weakness lower limb | 1 (4.3) | 1 (8.3) | 0 (0) |
| Respiratory failure | 1 (4.3) | 1 (8.3) | 0 (0) |
| Somnolence | 1 (4.3) | 1 (8.3) | 0 (0) |
| Thromboembolic event | 1 (4.3) | 1 (8.3) | 0 (0) |
| Wound infection | 1 (4.3) | 1 (8.3) | 0 (0) |
Data are number (%). Treatment-emergent adverse events (AEs) possibly, probably, or definitely related to JCAR021 or other study procedures. Grade per National Cancer Institute’s Common Terminology Criteria for Adverse Events version 4.03. Grade 3-5 AEs were collected.
PTT, partial thromboplastin time.